These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30121967)

  • 1. Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro.
    Koh HK; Seo SY; Kim JH; Kim HJ; Chie EK; Kim SK; Kim IH
    Cancer Res Treat; 2019 Apr; 51(2):696-705. PubMed ID: 30121967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
    Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines.
    Kirstein A; Schilling D; Combs SE; Schmid TE
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
    Bobola MS; Kolstoe DD; Blank A; Silber JR
    Mol Cancer Ther; 2010 May; 9(5):1208-18. PubMed ID: 20457618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage.
    Paranjpe A; Zhang R; Ali-Osman F; Bobustuc GC; Srivenugopal KS
    Carcinogenesis; 2014 Mar; 35(3):692-702. PubMed ID: 24193513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repositioning disulfiram as a radiosensitizer against atypical teratoid/rhabdoid tumor.
    Lee YE; Choi SA; Kwack PA; Kim HJ; Kim IH; Wang KC; Phi JH; Lee JY; Chong S; Park SH; Park KD; Hwang DW; Joo KM; Kim SK
    Neuro Oncol; 2017 Aug; 19(8):1079-1087. PubMed ID: 28340172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
    Zirjacks L; Stransky N; Klumpp L; Prause L; Eckert F; Zips D; Schleicher S; Handgretinger R; Huber SM; Ganser K
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma.
    Yun HS; Kramp TR; Palanichamy K; Tofilon PJ; Camphausen K
    Sci Rep; 2024 May; 14(1):12363. PubMed ID: 38811596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H; Lin H; Zhang X; Li J
    Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
    Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
    Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
    Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
    Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
    Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
    Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.